PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Targeting Human Epidermal Growth Factor Receptor 2 (HER2) in colorectal cancer stem cells (CR-CSCs) shows promise. Combination therapy including HER2, Phosphatidylinositol 3-kinase (PI3K), and Mitogen-Activated Protein Kinase Kinase (MEK) inhibitors can overcome resistance and reduce tumor growth.
Area Of Science
- Oncology
- Cancer Stem Cell Biology
- Molecular Targeted Therapy
Background
- Cancer stem cells (CSCs) drive tumor progression and recurrence in colorectal cancer (CRC).
- Human Epidermal Growth Factor Receptor 2 (HER2) overexpression is a poor prognostic indicator in CRC and a targetable vulnerability.
- Resistance to anti-Epidermal Growth Factor Receptor (EGFR) therapies poses a significant clinical challenge.
Purpose Of The Study
- To investigate HER2 expression in colorectal cancer stem cells (CR-CSCs).
- To evaluate the therapeutic potential of targeting HER2 in anti-EGFR resistant CRC.
- To elucidate mechanisms of therapy resistance in CR-CSCs.
Main Methods
- Generation of CR-CSC mouse avatars from patient-derived xenografts.
- Chromatin immunoprecipitation sequencing (ChIP-seq) for transcriptional analysis of HER2.
- Global RNA sequencing (RNA-seq) to identify resistance mechanisms.
- In vivo preclinical validation of combination therapies.
Main Results
- High HER2 expression in CD44v6+ CR-CSCs correlates with Phosphatidylinositol 3-Kinase (PI3K)/AKT pathway activation.
- Combined HER2, PI3K, and MEK inhibition induces CR-CSC death and tumor regression in xenografts, including those with Kras/Pik3ca mutations.
- Cancer-associated fibroblasts contribute to CR-CSC resistance via cytokine release, necessitating triple targeting.
- PI3K/AKT inhibition alone effectively targets liver-disseminating CR-CSCs in an adjuvant therapy model.
Conclusions
- Targeting HER2 in combination with PI3K and MEK inhibitors is crucial for overcoming anti-EGFR therapy resistance in CRC.
- PI3K inhibition alone is effective against disseminated CR-CSCs in the adjuvant setting.
- These findings support the rationale for clinical trials in both adjuvant and metastatic CRC settings.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...